Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Liraglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.
any
Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)
180-225mg enteric-coated peppermint oil, 2-3 times daily before meals
before-meals
Enteric-coated capsules
Weeks to months
Months (titrated over weeks)
Months to years
Especially during dose escalation
Within hours to 4 weeks
Days to weeks
Soon after dosing
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).
N Engl J Med (2016) · Rct · n=9340
Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide (up to 1.8 mg/day) vs placebo, median follow-up 3.8 years
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).
N Engl J Med (2015) · Rct · n=3731
56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
JAMA (2015) · Rct · n=846
56-week double-blind RCT in 846 adults with overweight/obesity AND type 2 diabetes, liraglutide 3.0 mg vs 1.8 mg vs placebo (2:1:1)
The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data.
BMC Complement Altern Med (2019) · Meta analysis · n=835
12 randomized trials, 835 patients pooled
Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis.
J Clin Gastroenterol (2014) · Meta analysis · n=726
9 randomized placebo-controlled trials, 726 patients
Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis.
Complement Ther Med (2020) · Meta analysis
33 double-blind placebo-controlled trials reviewed; 17 evaluated peppermint oil
Liraglutide has a higher evidence score (7.5/10 vs 7/10) and wins in 2 of 3 categories.
No known interactions between Liraglutide and Peppermint Oil have been documented in our database. However, always consult a healthcare provider before combining supplements.